NanoenTek,Inc.
Financials
Valuation Metrics
NanoenTek,Inc.'s Market Cap is ₩1392B. At end of 2025 it was ₩2286B. Ranked #1021 of 2,436 in KR market (top 42%), #506 of 1,649 on KOSDAQ (top 31%), #120 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 51%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 139.23B KRW | KR#1,021/2,436 Sec#120/234 |
| Revenue | 40.66B KRW | KR#1,888/2,436 Sec#131/234 |
| Net Income | 2.65B KRW | KR#1,296/2,436 Sec#89/234 |
| Total Assets | 100.68B KRW | KR#1,737/2,436 Sec#140/234 |
| Net Assets | 92.04B KRW | KR#1,455/2,436 Sec#118/234 |
| Employees | 138 | KR#1,381/2,436 Sec#112/234 |
| Value | ||
| P/E | 52.48x | KR#1,359/2,436 Sec#88/234 |
| P/B | 1.51x | KR#1,792/2,436 Sec#129/234 |
| PEG | 0.18x | KR#497/2,436 Sec#27/234 |
| P/S | 3.42x | KR#2,050/2,436 Sec#132/234 |
| EV/EBITDA | 108.57x | KR#1,471/2,436 Sec#102/234 |
| FCF Yield | 1.71% | KR#1,095/2,436 Sec#75/234 |
| Profitability | ||
| ROE | 2.88% | KR#1,241/2,436 Sec#88/234 |
| ROA | 2.64% | KR#1,013/2,436 Sec#85/234 |
| Op. Margin | 2.88% | KR#1,243/2,436 Sec#95/234 |
| Revenue Growth | 31.74% | KR#458/2,436 Sec#40/234 |
| Earnings Growth | 287.02% | KR#183/2,436 Sec#11/234 |
| Financial Health | ||
| Debt Ratio | 109.38% | KR#426/2,436 Sec#60/234 |
| FCF | 2.37B KRW | KR#1,055/2,436 Sec#74/234 |
| Cash | 12.30B KRW | KR#1,546/2,436 Sec#118/234 |
| Current Ratio | 10.44x | KR#95/2,436 Sec#25/234 |
| Net Debt/EBITDA | -10.52x | KR#63/2,436 Sec#2/234 |
| Performance | ||
| 1Y Return | 6.10% | KR#651/2,436 Sec#45/234 |
| 1M Return | -7.35% | KR#1,421/2,436 Sec#131/234 |
| From 52W High | -61.08% | KR#1,734/2,436 Sec#143/234 |
| 1Y MDD | -57.30% | KR#1,268/2,436 Sec#104/234 |
| Trading | ||
| Volume | 178,137 shares | KR#464/2,436 Sec#40/234 |
| Foreign Own. | 1.25% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 76 KRW | KR#1,403/2,436 Sec#98/234 |
| BPS | 2,432 KRW | KR#1,926/2,436 Sec#156/234 |
Company Info
NanoEnTek, established in 1987 as an information security business and rebranded in 2006, is headquartered in Guro-gu, Seoul. The company, slated to become a subsidiary of AAI Healthcare in 2025, specializes in Lab-on-a-chip based in-vitro diagnostic devices and immunodiagnostic systems. Its FREND System has received FDA approval and is stably supplied in North America. Utilizing Bio-MEMS and microfluidic technology, NanoEnTek conducts precise clinical tests, holding 108 registrations and expanding its business globally.